2021
MP62-17 ENZALUTAMIDE IN PATIENTS WITH LOCALIZED PROSTATE CANCER UNDERGOING ACTIVE SURVEILLANCE: ENACT
Shore N, Renzulli J, Fleshner N, Hollowell C, Vourganti S, Silberstein J, Siddiqui R, Hairston J, Elsouda D, Russell D, Cooperberg M, Tomlins S. MP62-17 ENZALUTAMIDE IN PATIENTS WITH LOCALIZED PROSTATE CANCER UNDERGOING ACTIVE SURVEILLANCE: ENACT. Journal Of Urology 2021, 206: e1099-e1099. DOI: 10.1097/ju.0000000000002102.17.Peer-Reviewed Original Research
2020
A comparison of sipuleucel-T (sip-T) product parameters from two phase III studies: PROVENT in active surveillance prostate cancer and IMPACT in metastatic castrate-resistant prostate cancer (mCRPC).
Ross A, Armstrong A, Pieczonka C, Bailen J, Tutrone R, Cooperberg M, Pavlovich C, Renzulli J, Haynes H, Sheikh N, Shore N. A comparison of sipuleucel-T (sip-T) product parameters from two phase III studies: PROVENT in active surveillance prostate cancer and IMPACT in metastatic castrate-resistant prostate cancer (mCRPC). Journal Of Clinical Oncology 2020, 38: 321-321. DOI: 10.1200/jco.2020.38.6_suppl.321.Peer-Reviewed Original ResearchMetastatic castrate-resistant prostate cancerCD54 upregulationProstate cancerOverall survivalActive surveillanceCell countCastrate-resistant prostate cancerPeripheral blood mononuclear cellsEarly-stage prostate cancerAutologous cellular immunotherapyLarger immune responsesPhase III studyBlood mononuclear cellsStage prostate cancerTotal nucleated cell countNucleated cell countIII studyCellular immunotherapyMononuclear cellsTreatment weekProstate adenocarcinomaT cellsImmune responseTNC countProvent